跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 31 条关于
“Helsana HealthInvest”
全部
31
临床试验
5
药物
6
机构
7
资讯
13
去年
Hedera Dx Secures €15 Million Series A to Expand Decentralized Liquid Biopsy Platform Across Europe
上个月
Why Drug Development Costs Are Rising: A 65% Jump in a Decade
去年
Mersana Therapeutics Stock Drops Following Phase 1 Trial Data Release
10个月前
Day One Biopharmaceuticals Acquires Mersana Therapeutics for $129M, Targeting Rare Cancer Treatment
去年
MediPharm Labs Extends Deadline for $5.5M Napanee Facility Sale to Kensana Health
去年
Mersana Therapeutics Receives Buy Rating Based on Promising Clinical Data and Strong Financials
10个月前
Day One Biopharmaceuticals Acquires Mersana Therapeutics for $25 Per Share in $285 Million Deal
去年
Helsinn Submits New AKYNZEO® Formulation to EMA for Chemotherapy-Induced Nausea and Vomiting
8个月前
Day One Biopharmaceuticals Reports Strong OJEMDA Revenue Growth and Expands Pipeline Through Mersana Acquisition
去年
Emiltatug Ledadotin (XMT-1660) Shows Promise in Phase 1 Trial, Receives FDA Fast Track for Advanced Breast Cancer
第 1 页,共 2 页
上一页
下一页